JMIR Research Protocols (Jul 2022)

Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study

  • Joy Burns,
  • Patrick Rivers,
  • Lindsay B LeClair,
  • Krystal S Jovel,
  • Ramona P Rai,
  • Ashley A Lowe,
  • Laura J Edwards,
  • Sana M Khan,
  • Clare Mathenge,
  • Maria Ferraris,
  • Jennifer L Kuntz,
  • Julie Mayo Lamberte,
  • Kurt T Hegmann,
  • Marilyn J Odean,
  • Hilary McLeland-Wieser,
  • Shawn Beitel,
  • Leah Odame-Bamfo,
  • Natasha Schaefer Solle,
  • Josephine Mak,
  • Andrew L Phillips,
  • Brian E Sokol,
  • James Hollister,
  • Jezahel S Ochoa,
  • Lauren Grant,
  • Matthew S Thiese,
  • Keya B Jacoby,
  • Karen Lutrick,
  • Felipe A Pubillones,
  • Young M Yoo,
  • Danielle Rentz Hunt,
  • Katherine Ellingson,
  • Mark C Berry,
  • Joe K Gerald,
  • Joanna Lopez,
  • Lynn B Gerald,
  • Meredith G Wesley,
  • Karl Krupp,
  • Meghan K Herring,
  • Purnima Madhivanan,
  • Alberto J Caban-Martinez,
  • Harmony L Tyner,
  • Jennifer K Meece,
  • Sarang K Yoon,
  • Ashley L Fowlkes,
  • Allison L Naleway,
  • Lisa Gwynn,
  • Jefferey L Burgess,
  • Mark G Thompson,
  • Lauren EW Olsho,
  • Manjusha Gaglani

DOI
https://doi.org/10.2196/37929
Journal volume & issue
Vol. 11, no. 7
p. e37929

Abstract

Read online

BackgroundAssessing the real-world effectiveness of COVID-19 vaccines and understanding the incidence and severity of SARS-CoV-2 illness in children are essential to inform policy and guide health care professionals in advising parents and caregivers of children who test positive for SARS-CoV-2. ObjectiveThis report describes the objectives and methods for conducting the Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT) study. PROTECT is a longitudinal prospective pediatric cohort study designed to estimate SARS-CoV-2 incidence and COVID-19 vaccine effectiveness (VE) against infection among children aged 6 months to 17 years, as well as differences in SARS-CoV-2 infection and vaccine response between children and adolescents. MethodsThe PROTECT multisite network was initiated in July 2021, which aims to enroll approximately 2305 children across four US locations and collect data over a 2-year surveillance period. The enrollment target was based on prospective power calculations and accounts for expected attrition and nonresponse. Study sites recruit parents and legal guardians of age-eligible children participating in the existing Arizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (HEROES)-Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) network as well as from surrounding communities. Child demographics, medical history, COVID-19 exposure, vaccination history, and parents/legal guardians’ knowledge and attitudes about COVID-19 are collected at baseline and throughout the study. Mid-turbinate nasal specimens are self-collected or collected by parents/legal guardians weekly, regardless of symptoms, for SARS-CoV-2 and influenza testing via reverse transcription-polymerase chain reaction (RT-PCR) assay, and the presence of COVID-like illness (CLI) is reported. Children who test positive for SARS-CoV-2 or influenza, or report CLI are monitored weekly by online surveys to report exposure and medical utilization until no longer ill. Children, with permission of their parents/legal guardians, may elect to contribute blood at enrollment, following SARS-CoV-2 infection, following COVID-19 vaccination, and at the end of the study period. PROTECT uses electronic medical record (EMR) linkages where available, and verifies COVID-19 and influenza vaccinations through EMR or state vaccine registries. ResultsData collection began in July 2021 and is expected to continue through the spring of 2023. As of April 13, 2022, 2371 children are enrolled in PROTECT. Enrollment is ongoing at all study sites. ConclusionsAs COVID-19 vaccine products are authorized for use in pediatric populations, PROTECT study data will provide real-world estimates of VE in preventing infection. In addition, this prospective cohort provides a unique opportunity to further understand SARS-CoV-2 incidence, clinical course, and key knowledge gaps that may inform public health. International Registered Report Identifier (IRRID)RR1-10.2196/37929